Roy Lester Freeman - Jun 24, 2022 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Milton H. Werner, attorney-in-fact
Stock symbol
IKT
Transactions as of
Jun 24, 2022
Transactions value $
$0
Form type
4
Date filed
6/28/2022, 09:00 PM
Previous filing
Jun 29, 2021
Next filing
Jul 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (right to buy) Award $0 +40K $0.00 40K Jun 24, 2022 Common Stock 40K $0.81 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This entire stock option grant will vest 100% in a single tranche on the earlier of June 24, 2023 or the day prior to the next annual meeting of stockholders.